Lead Product(s): Dotinurad
Therapeutic Area: Rheumatology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 25, 2020
Under this agreement, Eisai will proceed with the development of dotinurad in China.